Four standardized clinical courses have been established for MS: Relapsing-remitting MS – Acute episodes of Neurological symptoms accompanied by periods of a few months to years of relative noiseless with no new symptoms of disease activity. This describes the original course of 80 percent of individuals with MS. Primary progressive MS – About 10-15 percent of the MS population experience no relapses, but have problems with gradual starting point of disability. Secondary relapsing-remitting MS – This describes about 60-65 percent of the people suffering from MS who began with relapsing-remitting MS and then relapses diminish in frequency or cease entirely who then begin to have progressive neurologic decline. The median time between disease conversion and onset from relapsing-remitting to secondary progressive MS is 15-19 years.Participants were then randomly assigned to receive 0 g , 1.25 g, 2.5 g, 5 g, or 10 g of a topical 1 percent testosterone gel daily for 16 weeks. Participants in cohort 2 also received anastrozole at a dosage of just one 1 mg daily to block the aromatization of testosterone to estrogen. Participants were unaware of the study-group assignments. Individuals were seen every four weeks. At each visit, fasting blood samples were attained to measure gonadal steroid amounts, and questionnaires had been administered to assess physical function, health status, vitality, and sexual function. At baseline and week 16, body fat and lean mass had been assessed through dual-energy x-ray absorptiometry ; subcutaneous – and intraabdominal-excess fat areas and thigh-muscle area were measured by way of computed tomography ; and lower-extremity strength was determined by method of a leg press.